Short-Term Risk of Colorectal Cancer in Individuals With Lynch Syndrome: A Meta-Analysis

被引:29
作者
Jenkins, Mark A. [1 ]
Dowty, James G. [1 ]
Ouakrim, Driss Ait [1 ]
Mathews, John D. [1 ]
Hopper, John L. [1 ,2 ]
Drouet, Youenn [3 ,4 ]
Lasset, Christine [3 ,4 ]
Bonadona, Valerie [3 ,4 ]
Win, Aung Ko [1 ]
机构
[1] Univ Melbourne, Ctr Biostat & Epidemiol, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3052, Australia
[2] Seoul Natl Univ, Inst Hlth & Environm, Sch Publ Hlth, Seoul, South Korea
[3] Univ Lyon 1, CNRS, Unite Mixte Rech 5558, Lab Biomerie & Biol Evolut, F-69622 Villeurbanne, France
[4] Ctr Leon Berard, F-69373 Lyon, France
基金
英国医学研究理事会;
关键词
MUTATION CARRIERS; GENE; RECOMMENDATIONS; GUIDELINES; FAMILY; HMLH1; HMSH2; MLH1; MSH2;
D O I
10.1200/JCO.2014.55.8536
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose For carriers of germline mutations in DNA mismatch repair genes, the most relevant statistic for cancer prevention is colorectal cancer (Lynch syndrome) risk, particularly in the short term. Methods We conducted a meta-analysis of all independent published Lynch syndrome studies reporting age-and sex-dependent colorectal cancer risks. We estimated 5-year colorectal cancer risk over different age groups, separately for male and female mutation carriers, and number needed to screen to prevent one death. Results We pooled estimates from analyses of 1,114 Lynch syndrome families (508 with MLH1 mutations and 606 with MSH2 mutations). On average, one in 71 male and one in 102 female MLH1 or MSH2 mutation carriers in their 20s will be diagnosed with colorectal cancer in the next 5 years. These colorectal cancer risks increase with age, peaking in the 50s (one in seven males and one in 12 females), and then decrease with age (one in 13 males and one in 19 females in their 70s). Annual colonoscopy in 16 males or 25 females in their 50s would prevent one death from colorectal cancer over 5 years while resulting in almost no serious complications. In comparison, annual colonoscopy in 155 males or 217 females in their 20s would prevent one death while resulting in approximately one serious complication. Conclusion For MLH1 or MSH2 mutation carriers, current guidelines recommend colonoscopy every 1 to 2 years starting in their 20s. Our findings support this regimen from age 30 years; however, it might not be justifiable for carriers who are in their 20s. (C) 2014 by American Society of Clinical Oncology
引用
收藏
页码:326 / U193
页数:8
相关论文
共 19 条
  • [1] Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome
    Bonadona, Valerie
    Bonaiti, Bernard
    Olschwang, Sylviane
    Grandjouan, Sophie
    Huiart, Laetitia
    Longy, Michel
    Guimbaud, Rosine
    Buecher, Bruno
    Bignon, Yves-Jean
    Caron, Olivier
    Colas, Chrystelle
    Nogues, Catherine
    Lejeune-Dumoulin, Sophie
    Olivier-Faivre, Laurence
    Polycarpe-Osaer, Florence
    Nguyen, Tan Dat
    Desseigne, Francoise
    Saurin, Jean-Christophe
    Berthet, Pascaline
    Leroux, Dominique
    Duffour, Jacqueline
    Manouvrier, Sylvie
    Frebourg, Thierry
    Sobol, Hagay
    Lasset, Christine
    Bonaiti-Pellie, Catherine
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2304 - 2310
  • [2] Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario
    Choi, Yun-Hee
    Cotterchio, Michelle
    McKeown-Eyssen, Gail
    Neerav, Monga
    Bapat, Bharati
    Boyd, Kevin
    Gallinger, Steven
    McLaughlin, John
    Aronson, Melyssa
    Briollais, Laurent
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2009, 7
  • [3] Curado M.P. E., 2007, Cancer Incidence in Five Continents, VIX
  • [4] Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study
    Dove-Edwin, I
    Sasieni, P
    Adams, J
    Thomas, HJW
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7524): : 1047 - 1049
  • [5] Cancer Risks for MLH1 and MSH2 Mutation Carriers
    Dowty, James G.
    Win, Aung K.
    Buchanan, Daniel D.
    Lindor, Noralane M.
    Macrae, Finlay A.
    Clendenning, Mark
    Antill, Yoland C.
    Thibodeau, Stephen N.
    Casey, Graham
    Gallinger, Steve
    Le Marchand, Loic
    Newcomb, Polly A.
    Haile, Robert W.
    Young, Graeme P.
    James, Paul A.
    Giles, Graham G.
    Gunawardena, Shanaka R.
    Leggett, Barbara A.
    Gattas, Michael
    Boussioutas, Alex
    Ahnen, Dennis J.
    Baron, John A.
    Parry, Susan
    Goldblatt, Jack
    Young, Joanne P.
    Hopper, John L.
    Jenkins, Mark A.
    [J]. HUMAN MUTATION, 2013, 34 (03) : 490 - 497
  • [6] Population carrier frequency of hMSH2 and hMLH1 mutations
    Dunlop, MG
    Farrington, SM
    Nicholl, I
    Aaltonen, L
    Petersen, G
    Porteous, M
    Carothers, A
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 (12) : 1643 - 1645
  • [7] The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means?
    Hampel, Heather
    de la Chapelle, Albert
    [J]. CANCER PREVENTION RESEARCH, 2011, 4 (01) : 1 - 5
  • [8] Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer
    Järvinen, HJ
    Aarnio, M
    Mustonen, H
    Aktan-Collan, K
    Aaltonen, LA
    Peltomäki, P
    de la Chapelle, A
    Mecklin, JP
    [J]. GASTROENTEROLOGY, 2000, 118 (05) : 829 - 834
  • [9] Hereditary non-polyposis colorectal cancer: The rise and fall of a confusing term
    Jass, Jeremy R.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (31) : 4943 - 4950
  • [10] Cancer risks for mismatch repair gene mutation carriers: A population-based early onset case-family study
    Jenkins, MA
    Baglietto, L
    Dowty, JG
    Van Vliet, CM
    Smith, L
    Mead, LJ
    Macrae, FA
    St John, DJB
    Jass, JR
    Giles, GG
    Hopper, JL
    Southey, MC
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (04) : 489 - 498